Xlife Sciences AG (XSWX:XLS) Altman Z2-Score: 1.36 (As of Jun. 25, 2026) — 35% Below Median


XSWX:XLS Xlife Sciences AG XSWX:XLS
50 GF Score
Price CHF20.90
GF Value CHF7.30
Valuation Significantly Overvalued
! 13 Warning Signs
View Full Analysis

What is Xlife Sciences AG Altman Z2-Score?

Xlife Sciences AG XSWX:XLS -11.06% 50 Altman Z2-Score is 1.36 as of Jun. 25, 2026, which is 35% below its 10-year median of 2.10. GuruFocus rates XSWX:XLS with a GF Score™ of 50/100 and a GF Value™ of CHF7.30 (Significantly Overvalued). The stock has 13 warning signs investors should review. Among 1,399 Biotechnology companies, Xlife Sciences AG ranks better than 58.33% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Xlife Sciences AG has a Altman Z2-Score of 1.36, indicating it is in Grey Zones. This implies that Xlife Sciences AG is in some kind of financial stress. If it is below 1.1, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Xlife Sciences AG's Altman Z2-Score or its related term are showing as below:

XSWX:XLS' s Altman Z2-Score Range Over the Past 10 Years
Min: 1.36   Med: 2.1   Max: 3.3
Current: 1.36

During the past 8 years, Xlife Sciences AG's highest Altman Z2-Score was 3.30. The lowest was 1.36. And the median was 2.10.


Xlife Sciences AG  (XSWX:XLS) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Xlife Sciences AG Altman Z2-Score Related Terms


Xlife Sciences AG Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Altman Z2-Score Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Altman Z2-Score
Get a 7-Day Free Trial 2.64 1.67 2.14 2.80 1.36

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.14 0.00 2.80 0.00 1.36

XSWX:XLS vs VRTX, REGN, ALNY: Altman Z2-Score Comparison

For the Biotechnology subindustry, Xlife Sciences AG's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xlife Sciences AG Altman Z2-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Xlife Sciences AG's Altman Z2-Score falls into.


XSWX:XLS
50GF Score
Xlife Sciences AG XSWX:XLS
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Xlife Sciences AG's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.0259+3.26*-0.0417+6.72*-0.0607+1.05*1.9794
=1.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2025:
Total Assets was CHF517.12 Mil.
Total Current Assets was CHF1.55 Mil.
Total Current Liabilities was CHF14.93 Mil.
Retained Earnings was CHF-21.55 Mil.
Pre-Tax Income was CHF-31.86 Mil.
Interest Expense was CHF-0.45 Mil.
Total Liabilities was CHF144.76 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1.553 - 14.93)/517.117
=-0.0259

X2=Retained Earnings/Total Assets
=-21.547/517.117
=-0.0417

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-31.86 - -0.449)/517.117
=-0.0607

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(286.529 - 0)/144.758
=1.9794

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Xlife Sciences AG has a Altman Z2-Score of 1.36 indicating it is in Grey Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 1.36 mean?
Xlife Sciences AG (XSWX:XLS) has a Altman Z2-Score of 1.36 as of Jun. 25, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Xlife Sciences AG and its competitors. This is 35% below median its historical median of 2.10. Over the past decade, Xlife Sciences AG's Altman Z2-Score has ranged from 1.36 to 3.30. According to the industry distribution chart, Xlife Sciences AG ranks #583 out of 1399 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Xlife Sciences AG's Altman Z2-Score too high?
Xlife Sciences AG's current Altman Z2-Score of 1.36 is 35% below median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 1.36 to a high of 3.30. Based on the distribution chart, Xlife Sciences AG ranks #583 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Altman Z2-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #583 out of 1399 companies for Altman Z2-Score. This puts Xlife Sciences AG in the upper half of its industry. Historically, Xlife Sciences AG's own Altman Z2-Score has ranged from 1.36 to 3.30 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Biotechnology company?
A good Altman Z2-Score depends on the Biotechnology industry context. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Altman Z2-Score is 1.36, which is 35% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.30, compared to a current price of CHF20.90 — trading 186.3% above its estimated fair value. The current Altman Z2-Score is 1.36, which is 35% below median its 10-year median of 2.10. Xlife Sciences AG's overall GF Score™ is 50/100 with 13 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Altman Z2-Score is 1.36 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF20.90 is trading 186.3% above its estimated GF Value™ of CHF7.30. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Altman Z2-Score: 1.36 (35% below median its 10-year median of 2.10)
  • GF Value™: CHF7.30 vs. price of CHF20.90 (186.3% above fair value)
  • GF Score™: 50/100 with 13 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
50GF Score

Get the complete analysis for XSWX:XLS

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF20.90
Price
CHF7.30
GF Value